Onco-Innovations Limited (W1H.F)
- Previous Close
0.9750 - Open
0.9950 - Bid 0.9700 x --
- Ask --
- Day's Range
0.9650 - 0.9950 - 52 Week Range
0.3227 - 2.0200 - Volume
21,420 - Avg. Volume
31,224 - Market Cap (intraday)
42.941M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.
oncoinnovations.comRecent News: W1H.F
View MorePerformance Overview: W1H.F
Trailing total returns as of 6/10/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: W1H.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: W1H.F
View MoreValuation Measures
Market Cap
42.95M
Enterprise Value
42.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
33.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-68.90%
Return on Equity (ttm)
-244.46%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-64.37k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
415.92k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--